Antibodies In-Depth Focus 2018
Posted: 6 September 2018 | Drug Target Review | No comments yet
In this In-Depth Focus, Stefan R. Schmidt discusses the current status and future perspectives of monoclonal antibodies and Tony Edge explains why the determination of aggregate is critical in the formation of monoclonal antibodies.
In this In-Depth Focus:
- Monoclonal antibody discovery: current status and future perspectives
Since the first description of how to generate monoclonal antibodies was published in the 1970s, this field of research has grown tremendously. Currently, more than 70 full-length antibodies or fragments are approved by the major regulatory agencies globally. Looking back, a lot has changed since this historic discovery.
- Aggregate formation for monoclonal antibodies
Workflows are generated around the analysis of large protein-derived therapeutics. The use of different analytical techniques is necessary to support drug development and testing, and thus increase generation of these new therapies. One of the areas that is most critical to this process is the determination of aggregates.
This In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Antibodies, Monoclonal Antibody
Carterra, IntelliCyt Corporation